Untitled

Abstract

The most widely practiced type of transplantation in humans is penetrating keratoplasty. Irreversible immune rejection of the transplanted cornea is the major cause of human allograft failure in the intermediate and late postoperative period. This immunological process causes reversible or irreversible damage to the grafted cornea in several cases despite the use of intensive immunosuppressive therapy. Management of corneal graft rejection consists of early detection and aggressive therapy with corticosteroids. Corticosteroid therapy, both topical and systemic, is the mainstay of management. Addition of immunosuppressive to the treatment regimen helps in quick and long-term recovery. Corneal graft failure after graft rejection remains an important cause of blindness and hence the need for developing new strategies for suppressing graft rejection is colossal.